Pharmacokinetics Study of Swertiamain of Mongolian Medicine DIGEDA-4 Decoction in Acute Liver Lesion Rat

BAI Mei-rong; BA-GEN Na; LA XINA Mujila; GAO Yu-feng

您当前的位置：

首页 >

文章列表页 >

Pharmacokinetics Study of Swertiamain of Mongolian Medicine DIGEDA-4 Decoction in Acute Liver Lesion Rat

更新时间：2024-01-04

- Pharmacokinetics Study of Swertiamain of Mongolian Medicine DIGEDA-4 Decoction in Acute Liver Lesion Rat
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 18, Issue 6, Pages: 125-128(2012)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2012
- 稿件说明：
移动端阅览
BAI Mei-rong, BA-GEN Na, LA XINA Mujila, et al. Pharmacokinetics Study of Swertiamain of Mongolian Medicine DIGEDA-4 Decoction in Acute Liver Lesion Rat[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(6): 125-128.
DOI：

BAI Mei-rong, BA-GEN Na, LA XINA Mujila, et al. Pharmacokinetics Study of Swertiamain of Mongolian Medicine DIGEDA-4 Decoction in Acute Liver Lesion Rat[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(6): 125-128. DOI：

摘要

目的: 建立急性肝损伤模型大鼠血清中獐牙菜苦苷的HPLC血药浓度测定方法

并对其药代动力学进行研究。方法: SD大鼠腹腔注射D-半乳糖胺(D-GIaN) (400 mg·kg-1)

制备急性肝损伤模型

按高、中、低(0.39

0.77

1.54 g·kg-1)剂量灌胃给予地格达-4味汤

收集不同时间点含药血清

HPLC测定血药浓度

采用Winnonlin 5.1药动学软件拟合房室模型

计算其药动学参数。结果: 獐牙菜苦苷在0.000 6~0.019 2 mg·L-1 (r=0.998 9) 线性关系良好

平均回收率均在80%以上

方法学考察其他项均符合实验要求。地格达-4味汤高、中、低剂量组吸收半衰期基本一致

药时曲线下面积(AUC)与给药剂量之间呈现良好的线性关系

属于线性动力学过程。结论: 獐牙菜苦苷在急性肝损伤模型大鼠体内的药时曲线符合二室模型特征;所建立的方法准确

灵敏度高

专属性好

可作为獐牙菜苦苷体内血清药物浓度分析方法。

Abstract

Objective: To establish a high performance liquid chromatography(HPLC) method for determining the serum concentration of swertiamain in acute liver damage rat and to investigate pharmacokinetics of swertiamain. Method: The model of acute liver damage rat was established by D-galactosamine(D-GIaN) 400 mg·kg-1 intraperitoneal injection. After the rats were administered by DIGEDA-4 decoction

HPLC was used to determine the serum concentration of swertiamain at different times; Winnonlin 5: 1 procedure was used to calculate concentration-time data and pharmacokinetic parameters. Result: The linearity were ranged from 0.15-4.8 μg·L-1 (r=0.998 9) and the average recovery was higher than 80%. Methodology investigation was all complied with the requirements. After oral administration of DIGEDA-4 decoction

the T1/2 was similar

the relationship between dose and AUC showed good linearity. Conclusion: The swertiamain was fitted to be a two-compartment model in acute liver damage rat. The method described in this report was accurate and has high sensitivity and selectivity which can be used to analyze quantitatively the serum concentration of swertiamain of the DIGEDA-4 decoction.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparison of Pharmacokinetics and Tissue Distribution of Free Anthraquinones and Gallic Acid in Mice with Ulcerative Colitis Before and After Processing of Rhei Radix et Rhizoma Carbonisata

Pharmacokinetic Differences of Seven Components in Different Phases of Banxia Xiexintang in Rats

Pharmacological Mechanism of Huanglian Jiedutang： A Review

Pharmacokinetic Analysis of Ziyuglycoside Ⅰ in Normal and Acute Kidney Injury Rats

Identification of Pharmacodynamic Material Basis of Ruyi Zhenbaowan by Multidimensional Correlation Model of "Pharmacodynamic-target-component-pharmacokinetic"

Related Author

SUN Jing

QI Yunpeng

LI Siyuan

HU Yingbo

ZHONG Linying

CHEN Jianbo

DONG Ling

HE Chao

Related Institution

School of Life Sciences，Beijing University of Chinese Medicine

School of Pharmacy，Shanghai University of Traditional Chinese Medicine

First Teaching Hospital of Tianjin University of TCM

The Second Affiliated Hospital of Tianjin University of TCM

School of Graduate Studies，Tianjin University of Traditional Chinese Medicine（TCM）

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰